India's new clinical trial rules establish an accelerated pathway for new drug approvals, but affordability remains… https://t.co/uhVXDZGLfr
Access our insights: Life Sciences MCS content now available on the IHS Online Store
For those unfamiliar with our MCS, these are primary and secondary research driven reports on the healthcare industry's most topical and complex issues. We focus heavily on pricing and reimbursement and market access issues. For each study we conduct approximately 50 interviews with payers, industry executives, healthcare professionals and other relevant stakeholders and provide primary research insights with in-depth desk-based research.
The majority of our MCS adhere to a common framework, comprising of an in-depth report structured by country chapters, along with a study summary and full overview of our methodology. We also produce a highly visual and user-friendly "Cross Analysis" slide deck to summarise key findings and offer a comparative, cross-country view.
Some of our recent studies have covered inter- and intra-country tiered pricing, the landscape for precision medicine, market access in the Middle East and North Africa region, flexible pricing opportunities, and international reference pricing. Most of these titles are now available for immediate purchase and access on the IHS Online Store.
Combining our deep knowledge of the industry, native language abilities, and our set of tools and services such as PharmOnline International and World Markets Pricing & Reimbursement, our MCS enable us to bring you up-to-date and important insights that support your understanding of the business impact of key industry developments. We have supported our clients' workflows as they formulate pricing and life cycle strategies, monitor competitors and customers, plan realistic budgets and forecasts, and generally keep pace with market, technology and regulatory trends.
Visit the IHS Online Store to make a quick purchase, or contact us to discuss any customized needs you may have or to discuss any special bundles. Over the next few months our blog will cover some of the recent developments and implications of these pricing and market access issues. We hope you enjoy the series.
Cameron Lockwood is the manager of the life sciences EMEA consulting team at IHS
Posted 18 May 2016
- India issues new clinical trial rules to expedite new drug approvals
- Medicare X
- Pharmacare for all in Canada: Unlikely proposal to imminent threat
- Accuracy check: Norwegian health expenditure data
- Budget impact of passing a share of negotiated manufacturer rebates to patients at POS
- United States experience dramatic shift in public share of healthcare spending
- Population health outcomes of American patients under different drug access conditions
- Improving Access to Medication-Assisted Treatment for Opioid Use Disorder among the Commercially-insured US Population
Democrats explore creative ways to expand health insurance access with Medicare X https://t.co/kAsNBvtiuz
The creation of the Canadian Drug Agency and Pharmacare could mean big changes for drug prices https://t.co/8uMsHLXiAE